.png)
Agenzia Italiana del Farmaco
Direct communication with healthcare professionals on Natpar (parathyroid hormone) - Direct communication with healthcare professionals on Natpar (parathyroid hormone)
Direct communication with healthcare professionals on Natpar (parathyroid hormone)
Natpar (parathyroid hormone) 100 micrograms/dose powder and solvent for solution for injection: expected shortage from June 30th, 2022.
Summary:
- Due to manufacturing challenges, Takeda will be unable to supply the 100 micrograms/dose strength from approximately end of June 2022. The duration is unknown but is expected to last at least 6 months.
- Healthcare professionals are advised not to initiate any new patients on any strength of Natpar until the supply issue is resolved.
- For existing patients on 100 mcg once a day, once the 100 micrograms / dose strength is unavailable, healthcare professionals can prescribe an alternative dosing regimen, as per their independent clinical judgment (see details below).
- It is very important to closely monitor serum calcium levels and observe patients for signs and symptoms of hypocalcemia while carefully adjusting active vitamin D and supplemental calcium doses in all patients affected by Natpar 100 micrograms/dose shortage.
Published on: 29 April 2022
📊 Online “OsMed interattivo”, la piattaforma aggiornata con i dati più recenti su consumi e spesa d...
Vai al post →
Ogni anno il Rapporto OsMed offre una fotografia aggiornata dell’uso dei #farmaci in Italia.
Un ins...
Vai al post →
“Se non sei un medico, non fare il medico.”
Uno slogan semplice, ma che nasce da un problema ancora ...
Vai al post →
🗞️ Oggi a Milano una giornata significativa per l’Agenzia Italiana del Farmaco: per la prima volta ...
Vai al post →
AIFA e Procura di Velletri firmano il protocollo d’intesa per il contrasto alla violenza di genere
...
Vai al post →
💊 Se non sei un medico, non fare il medico. L’uso improprio degli #antibiotici ne limita l’efficaci...
Vai al post →
